Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6603622

CCCn1ccc2ccc3ncccc3c21.N

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 14/20 0.67
HTR2C P28335 14/20 0.67
HTR2B P41595 13/20 0.67
CYP3A4 P08684 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 1/20 0.41
PDE10A Q9Y233 1/20 0.40
GRM2 Q14416 1/20 0.38
EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6607986 0.99 HTR2A (0.66) HTR2AHTR2CHTR2BCYP3A4KDM4E
Fumaric Acid SCHEMBL6602844 0.89 HTR2A (0.56) HTR2AHTR2CHTR2BCYP3A4PDE10A
SCHEMBL905948 0.82 HTR2A (0.62) HTR2AHTR2CHTR2BCYP3A4KDM4E
SCHEMBL6603614 0.81 HTR2C (1.00) HTR2AHTR2CHTR2BCYP3A4
SCHEMBL6604307 0.81 HTR2C (1.00) HTR2AHTR2CHTR2BCYP3A4
SCHEMBL6605040 0.81 HTR2C (1.00) HTR2AHTR2CHTR2BCYP3A4
Hydrochloric Acid SCHEMBL6604400 0.80 HTR2C (0.97) HTR2AHTR2CHTR2BCYP3A4
Hydrochloric Acid SCHEMBL6607981 0.80 HTR2C (0.97) HTR2AHTR2CHTR2BCYP3A4
Ammonia Solution, Strong SCHEMBL6604735 0.79 HTR2A (0.66) HTR2AHTR2CHTR2BCYP3A4KDM4E
SCHEMBL6602404 0.78 HTR2A (0.76) HTR2AHTR2CHTR2BCYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109809-B1 PYRROLOQUINOLINES FOR TREATMENT OF OBESITY CEREBRUS PHARM LTD (GB) 2004-11-17 EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 US disclosed